

## Lyme Disease Committee meeting 3

**Date:** 05/12/2016

**Location:** Wolfson Conference & Exhibition Space, 41 Portland Place,  
London W1B 1QH

**Minutes:** Confirmed

<b>Committee members present:</b>		
Saul Faust (SF) (Chair)		(Present for notes 1–5)
Srini Bandi (SB)		(Present for notes 1–5)
Stephen Barton (SBa)		(Present for notes 1–5)
Nick Beeching (NB)		(Present for notes 1–5)
Robin Brittain-Long (RBL)		(Present for notes 1–5)
Tim Brooks (TB)		(Present for notes 1–5)
Scott Hackett (SH)		(Present for notes 1–5)
Cheryl Hemingway (CH)		(Present for notes 1–5)
Neil Hopkinson (NH)		(Present for notes 1–5)
Veronica Hughes (VH)		(Present for notes 1–5)
Stella Huyshe-Shires (SHS)		(Present for notes 1–5)
Melissa McCullough (MM)		(Present for notes 4–5)
Caroline Rayment (CR)		(Present for notes 1–5)
David Stephens (DS)		(Present for notes 1–5)
<b>Co-opted expert</b>		
Nick Davies (ND)		(Present for notes 1–4b)

<b>In attendance:</b>		
Ben Doak (BD)	Guidelines Commissioning Manager, NICE	(Present for notes 1–5)
Catharine Baden-Daintree (CBD)	Senior Medical Editor, NICE	(Present for notes 1–5)
Ian Mather (IM)	Business Analyst, NICE	(Present for notes 1–4b)
Maria Cruickshank (MC)	Research Fellow, NGC	(Present for notes 1–5)
Meredith Faust (MF)	Document Editor/Process Assistant, NGC	(Present for notes 1–5)
Andreas Freitag (AF)	Senior Research Fellow, NGC	(Present for notes 1–5)

Rebecca Houghton (RH)	Clinical Trainee, NGC	(Present for notes 1–5)
Samantha Jones (SJ)	Project Manager, NGC	(Present for notes 1–5)
Sophia Kemmis-Betty (SKB)	Senior Health Economist, NGC	(Present for notes 1–5)
Norma O’Flynn (NOF)	Guideline Lead, NGC	(Present for notes 1–5)

<b>Apologies:</b>	
Jill Cobb (JC)	Information Specialist, NGC

**1. Welcome and objectives for the meeting**

The Chair welcomed the Committee members and attendees to the third meeting of the Lyme disease Guideline Committee. The Committee members and attendees introduced themselves.

The Chair informed the Committee that apologies had been received. These are noted above.

The Chair outlined the objectives of the meeting, which included the health economic plan, diagnostic review and draft review protocols.

**2. Confirmation of matter under discussion and declarations of interest**

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was Lyme disease management, health economics and diagnostics.

The Chair asked everyone to declare verbally any interests that have arisen since the last meeting.

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Saul Faust	Professor of Paediatric Immunology and Infectious Diseases, Director, Southampton NIHR Wellcome Trust Clinical Research Facility	Pfizer Global advisory board for adolescent immunization; Honorarium paid to University of Southampton.	Non-personal financial non-specific	Declare and participate

The Chair and a senior member of the Developer’s team noted that the interests declared did not prevent the attendees from fully participating in the meeting.

### **3. Minutes of the last meetings**

The Chair asked the Committee if it wanted to change the minutes of the last two meetings. The Committee agreed that the minutes were a true and accurate account of the meetings.

The Chair confirmed that all matters arising had been completed or were in hand.

BD confirmed that the guideline has been commissioned as a clinical guideline and does not include the prevention of Lyme disease.

### **4. Presentations and Discussions**

- a) SKB presented the draft health economic plan for the Committee's review.

The Committee then discussed the issues presented in relation to this guideline.

- b) AF presented an overview of the methodology, initial tests and evidence included in the diagnostic reviews for the Committee's review.

The Committee then discussed the issues presented in relation to this guideline.

- c) CBD presented on the role of the NICE editor and drafting recommendation guidance for the Committee's review.

CBD took questions from the group.

- d) AF led a discussion on the draft protocols for the management of Lyme disease as well as information for patients about Lyme disease.

### **5. Any other business**

None.

**Date of next meeting:** 24/01/17

**Location of next meeting:** Boardroom, National Guideline Centre, 180 Great Portland Street, London, W1W 5QZ.